Studies in animal models suggest that inflammation is a major contributor to secondary injury after intracerebral hemorrhage (ICH). Direct, noninvasive monitoring of inflammation in the human brain after ICH will facilitate early-phase development of anti-inflammatory treatments. We sought to investigate the feasibility of multimodality brain imaging in subacute ICH. 
Introduction
After intracerebral hemorrhage (ICH), extravasation of blood leads to immediate physical tissue injury. Secondary damage ensues over hours and days, mediated by a cascade of molecular and cellular events involving the toxic effects of blood components and sterile inflammation. 1 Within hours of onset, microglia become activated taking on a proinflammatory phenotype, releasing cytokines and chemokines that activate astrocytes and endothelial cells causing blood-brain barrier (BBB) breakdown (alongside the direct effects of the ICH), recruitment of circulating leukocytes, and exacerbation of perihematomal edema. 2 Previous clinical studies in ICH have largely focused on peripheral inflammatory markers showing associations between fever, elevated white blood cell count, interleukin-6 (IL-6), C-reactive protein (CRP), and fibrinogen on admission and worse subacute and long-term outcomes. 3 These clinical studies demonstrate the importance of the systemic inflammatory response, but provide no information on processes within the brain, where inflammation contributes directly to secondary injury. Given the growing interest in modulating inflammation in acute ICH and the failure in ischemic stroke to translate findings from animal models, a means of studying inflammation in the intact human brain after ICH is urgently required.
Using advanced multimodality imaging, it is possible to estimate the extent and distribution of microglial activation and BBB breakdown. When activated, microglia express the translocator protein 18 kDa (TSPO), normally present at very low levels in the central nervous system. [
11 C]-(R)-PK11195 binds to TSPO and has been used for PET studies of acute ischemic stroke, 4 but in vivo imaging of microglial activation in ICH has not been previously described. Using MRI and CT dynamic contrast-enhanced (DCE) techniques, two previous studies have quantified BBB breakdown after ICH. 5, 6 Combining this technique with [
11 C]-(R)-PK11195 PET will provide a more complete picture of the inflammatory response and allow an understanding of the extent that BBB breakdown colocalizes with microglial activation with important implications for the delivery of an anti-inflammatory drug to the brain. Our aim was to demonstrate the feasibility of combining these techniques in patients during the acute stage of ICH and describe hypothesisgenerating preliminary findings. a Based on modified Boston criteria b Confirmed on histology at later surgical resection. ICH = intracerebral hemorrhage; pg = picogram; mL = milliliter; l = liter; mg = milligram; GCS = Glasgow Coma Scale; PHE = peri-hematomal edema; CRP = C-reactive protein; DCE = dynamic contrast enhanced; K trans = volume transfer constant; IL = interleukin; CAA = cerebral amyloid angiopathy.
Methods
Patients between 4 and 28 days after onset of acute, spontaneous ICH were recruited from Salford Royal NHS Foundation Trust (Salford, UK) between 05/12/12 and 28/03/2014, following appropriate approvals. We excluded patients if they had a contraindication to MRI, were pregnant or breast feeding, had significant renal impairment, had an acute neurosurgical procedure performed or planned, or who were taking medications which were likely to interfere with MRI included T 1 -weighted volumetric Fast Field Echo (T 1 -FFE) imaging, T 2 -weighted fluid attenuated inversion recovery (FLAIR) imaging, and T 1 -weighted DCE-MRI. Parametric maps of the BBB transfer constant (K trans ) were generated from DCE-MRI data using an uptake model (details of MRI acquisition and analysis are given in Online Supplementary Methods). PET data were analyzed as previously described. 7 In brief, iterative ordered subset expectation maximization 3D method was used to reconstruct a quantitative series of dynamic images from the 60 minutes PET emission scan. A reference tissue input function was extracted from cerebellar gray matter in order to generate parametric maps of binding potential BP ND using the simplified reference tissue model. Using SPM (version 8), all maps and images were coregistered to the T 1 -weighted volume MRI. The T 1 -weighted volume image was segmented into gray matter and white matter probability maps and a maximum probability brain atlas 8 was warped into individual space. Two regions of interest (ROI) were defined manually from the 
Results
Five patients with acute ICH underwent research brain imaging between 5 and 25 days after onset as part of this feasibility study (Table 1 ). All patients tolerated the scans without difficulty except patient 3, who was unable to complete the last 22 minutes of the 60 minutes emission PET scan and was the only one to undergo both scans on 1 day. Etiologies confirmed using appropriate clinical imaging included a cavernous angioma, an arteriovenous malformation (Fig 1) , probable cerebral amyloid angiopathy, and small vessel disease due to chronic hypertension. [
11 C]-(R)-PK11195 binding was low in all hematomas. Patients 2 and 4 showed increased [
11 C]-(R)-PK11195 binding both within the perihematomal edema volume and the ipsilateral brain region (Fig 2) . Patients 1 and 4 underwent surgery at 3 and 12 months, respectively, with perlesional tissue demonstrating intense microglial activation. Analyses of DCE-MRI data show increases in K trans in the perihematomal edema volume (mean difference = 2.2 × 10 −3 minute −1 ; SD = 1.6 × 10 −3 minute −1 ) in all 5 patients relative to the contralateral. Visual inspection of images (Fig 2) consistently demonstrates a clear ring of increased K trans adjacent to the outer border of the hematoma. No pattern is suggested for a relationship between circulating inflammatory markers and imaging.
Discussion
Our small study is the first to show imaging of microglial activation with PET after ICH and demonstrates the feasibility of performing complex multimodality brain imaging after acute ICH. However, we found that performing PET and MR scans on different days may improve successful study completion. All patients show clear ring-shaped BBB breakdown in the outer border of the hematoma, suggesting that delivery of treatments with limited transfer across the intact BBB may be enhanced in acute ICH. We observed a heterogeneous pattern of [ 11 C]-(R)-PK11195 binding, with only 2 patients demonstrating enhanced binding around the hematoma. In neither case was the binding closely colocated with the BBB disruption, suggesting that factors other than microglial activation may drive BBB breakdown after ICH, an observation that should be investigated further in future studies. Late perilesional biopsies in 2 patients did show intense microglial activation, but only 1 had enhanced [
11 C]-(R)-PK11195 binding acutely. The long delay between PET and biopsies makes it difficult to interpret this disparity. We have demonstrated the feasibility of performing complex multimodality imaging to track the inflammatory response after ICH. This will be a vital tool in investigating this promising therapeutic target with potential use in early phase proof-of-concept clinical trials.
